About Pyxis Oncology
Our Vision
Liberate science to cure patients with cancer.
Our Mission
Our disruptive approach improves and extends life for patients with cancer and their families.
Pyxis Oncology is devoted to transforming the lives of patients with cancer by advancing our innovative and differentiated portfolio of biologics that specifically target tumor cells and overcome immune suppression. We believe that antibody-drug conjugates (ADCs) and immunotherapies offer unique potential to address difficult-to-treat cancers, leading to improved patient outcomes.

Established leadership
We have assembled a world class management team with deep experience in oncology research and development and a demonstrated track record of success, building public biotech companies and developing innovative medicines.
Executive team
Board of Directors
Scientific Advisory Board
Thomas Gajewski, M.D., Ph.D.
University of Chicago
Michael B. Atkins, M.D.
Georgetown Lombardi Comprehensive Cancer Center
Lisa H. Butterfield, Ph.D.
Parker Institute for Cancer Immunotherapy, University of California, San Francisco
Alan Korman, Ph.D.
Vir Biotechnology, Inc.
Jason J. Luke, M.D., FACP
UPMC Hillman Cancer Center and University of Pittsburgh
Christoph Rader, Ph.D.
The Scripps Research Institute
Anthony W. Tolcher, M.D., FRCP, FACP
NEXT Oncology
Technical Advisory Board
Morris Rosenberg, D.Sc.
TAB Chair
Founder & Consultant, MRosenberg BioPharma Consulting
Robert Baffi, Ph.D., MBA
President of Global Manufacturing & Technical Operations, BioMarin
V. Bryan Lawlis, Ph.D.
Director, Aeglea BioTherapeutics, Inc.;
Director, Geron Corporation
Christopher O’Donnell, Ph.D.
Vice President, WRDM and Partner at Pfizer Ventures
Michael Sun, Ph.D.
Crux CMC Consulting
Partners
We are always open to strategic partnerships that can help advance our mission to develop life-changing biologics for patients with cancer. We welcome you to get in touch.
Our partners:




Investors



















